Amber TX is a platform designed to generate novel, closed-loop, bioelectrical therapies. With a focus on the peripheral vs the central nervous system, Amber targets disease areas where adding closed-loop intelligence may radically improve clinical efficacy and outcomes. Our leading indication is mixed urinary incontinence, an unmet clinical need that affects up to 30% of patients in the total $30bn a year urinary incontinence market.
Location: United Kingdom, England, City of Westminster
Employees: 1-10
Total raised: $100M
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | Oxford Sci... | oxfordscie... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.06.2024 | Series A | $100M | - |
Mentions in press and media 6
| Date | Title | Description |
| 31.07.2024 | From labs to market: 10 promising biotech startups based in the UK | Biotechnology, or biotech, uses living organisms to create products and technologies that improve our lives. This field spans not only healthcare but also sectors such as agriculture, environmental protection, and industrial processes, lead... |
| 10.06.2024 | Breakthrough Amber-UI Therapy Secures $100 Million Financing for FDA Approval | In a groundbreaking development, Amber Therapeutics, a UK-based medical technology company, has successfully closed a substantial $100 million Series A financing round to propel their innovative Amber-UI neuromodulation therapy for mixed ur... |
| 10.06.2024 | Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval | US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI) By targeting the pudendal nerve, Amber-UI has the unique potential to treat the millions of women w... |
| 10.06.2024 | Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval | US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI) By targeting the pudendal nerve, Amber-UI has the unique potential to treat the millions of women w... |
| 24.01.2023 | Amber Therapeutics announces successful first-in-human implants of Amber-UI: an intelligent, closed-loop bioelectrical therapy for urge and mixed urinary incontinence | Amber-UI presents a unique and significant opportunity to treat urge and mixed urinary incontinence by targeting the pudendal nerve Amber-UI can sense, interpret, adapt and respond to individual patient signals to restore normal bladder fun... |
| - | Amber Therapeutics | “Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology” |